BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial
January 11, 2016 at 11:35 AM EST
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a ...